ROBIN BROWN: Open Payments
NPI 1134773922 · HAVRE DE GRACE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$661 in 36 payments from 11 companies in 2025. Trend: 2023 $756 · 2024 $661 · 2025 $661
Food & beverage: $592Education: $69
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $151 |
| Astellas Pharma US Inc | 3 | $118 |
| Hologic Sales and Service, LLC | 1 | $95 |
| Lilly USA, LLC | 4 | $85 |
| Novo Nordisk Inc | 2 | $49 |
| Exact Sciences Corporation | 2 | $48 |
| Amgen Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $18 |
Products named: APTIMA, QULIPTA, UBRELVY, MOUNJARO, Rybelsus, Veozah, The Cologuard Plus Collection Kit, OTEZLA.
Industry payments across MD — which companies pay providers there.
